Journal Article

Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography

Chiarenza, Maurizio, Chiti, Arturo, Infante, Maurizio, Angeli, Enzo, Destro, Anna, Errico, Valentina, Toschi, Luca, Chiesa, Giuseppe, Ciccarelli, Michele, Santoro, Armando, Cavina, Raffaele, Passera, Eliseo, Brambilla, Giorgio, Ferraroli, Giorgio, Aranzulla, Giuseppe, Alloisio, Marco, Cavuto, Silvio, Roncalli, Massimo, Bottoni, Edoardo, Navarria, Pierina, Finocchiaro, Giovanna, Lutman, Fabio Romano, Scorsetti, Marta, Voulaz, Emanuele

2015

Overview

Abstract Rationale Screening for lung cancer with low-dose spiral computed tomography (LDCT) has been shown to reduce lung cancer mortality by 20% compared with screening with chest X-ray (CXR) in the National Lung Screening Trial, but uncertainty remains concerning the efficacy of LDCT screening in a community setting. Objectives To explore the effect of LDCT screening on lung cancer mortality compared with no screening. Secondary endpoints included incidence, stage, and resectability rates. Methods Male smokers of 20+ pack-years, aged 60 to 74 years, underwent a baseline CXR and sputum cytology examination and received five screening rounds with LDCT or a yearly clinical review only in a randomized fashion. Measurements and Main Results A total of 1,264 subjects were enrolled in the LDCT arm and 1,186 in the control arm. Their median age was 64.0 years (interquartile range, 5), and median smoking exposure was 45.0 pack-years. The median follow-up was 8.35 years. One hundred four patients (8.23%) were diagnosed with lung cancer in the screening arm (66 by CT), 47 of whom (3.71%) had stage I disease; 72 control patients (6.07%) were diagnosed with lung cancer, with 16 (1.35%) being stage I cases. Lung cancer mortality was 543 per 100,000 person-years (95% confidence interval, 413–700) in the LDCT arm versus 544 per 100,000 person-years (95% CI, 410–709) in the control arm (hazard ratio, 0.993; 95% confidence interval, 0.688–1.433). Conclusions Because of its limited statistical power, the results of the DANTE (Detection And screening of early lung cancer with Novel imaging TEchnology) trial do not allow us to make a definitive statement about the efficacy of LDCT screening. However, they underline the importance of obtaining additional data from randomized trials with intervention-free reference arms before the implementation of population screening.

• Publisher: Oxford University Press
• Subject: Aged / Cause of Death / Comorbidity / Cost-Benefit Analysis / Early Detection of Cancer - methods / Early Detection of Cancer - statistics & numerical data / Follow-Up Studies / Humans / Incidence / Italy / Lung cancer / Lung Neoplasms - diagnosis / Lung Neoplasms - diagnostic imaging / Lung Neoplasms - mortality / Male / Medical screening / Middle Aged / Mortality / Neoplasm Staging / Outcome and Process Assessment (Health Care) / Radiography, Thoracic / Smoking - adverse effects / Smoking - epidemiology / Sputum - cytology / Tomography / Tomography, Spiral Computed - methods